Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications

被引：9

作者：

Borad, M. ^{[1
]}

Javle, M. ^{[2
]}

Shaib, W. L. ^{[3
]}

Mody, K. ^{[4
]}

Bergamo, F. ^{[5
]}

Harris, W. P. ^{[6
]}

Damjanov, N. ^{[7
]}

Macarulla, T. ^{[8
]}

Brandi, G. ^{[9
]}

Masi, G. ^{[10
]}

Busset, M. Droz Dit ^{[11
]}

Boncompagni, A. ^{[12
]}

Dimova-Dobreva, M. ^{[12
]}

Engelhardt, M. ^{[12
]}

Saulay, M. ^{[12
]}

Halfdanarson, T. R. ^{[13
]}

Knox, J. ^{[14
]}

Abou-Alfa, G. K. ^{[15
]}

Personeni, N. ^{[16
]}

Mazzaferro, V. ^{[17
]}

机构：

[1] Mayo Clin Canc Ctr, Dept Oncol, Scottsdale, AZ USA

[2] Univ Texas MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX USA

[3] Emory Univ, Hematol & Oncol, Atlanta, GA USA

[4] Mayo Clin, Hematol & Oncol, Jacksonville, FL USA

[5] IOV Ist Oncol Veneto IRCCS, Dipartimento Oncol 1, Padua, Italy

[6] Univ Washington, Med, Med Ctr, Seattle, WA USA

[7] Univ Penn, Abramson Canc Ctr, Hematol & Oncol, Philadelphia, PA USA

[8] Vall Hebron Inst Oncol, Med Oncol, VHIO Cellex Ctr, Barcelona, Spain

[9] Univ Bologna, Med Oncol, IRCCS Azienda Osped, Bologna, Italy

[10] AOU Pisana Stabilimento Santa Chiara, Oncol Med, Pisa, Italy

[11] Fdn IRCCS, Hepatopancreatobiliary & Digest Surg, Ist Nazl Tumori Milano, Milan, Italy

[12] Basilea Pharmaceut Ltd, Dept Dev, Basel, Switzerland

[13] Mayo Clin, Dept Med Oncol, Rochester, NY USA

[14] Princess Margaret Canc Ctr, Oncol Med, Toronto, ON, Canada

[15] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Dept Med, New York, NY USA

[16] Ist Clin Humanitas, Dept Oncol & Hematol, Rozzano, Italy

[17] Fdn IRCCS, Oncol Med, Ist Nazl Tumori Milano, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.087

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

59P

引用

页码：S567 / S568

页数：2

共 50 条

[1] Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
Busset, M. Droz Dit
Braun, S.
El-Rayes, B.
Harris, W. P.
Damjanov, N.
Masi, G.
Rimassa, L.
Bhoori, S.
Niger, M.
Personeni, N.
Braiteh, F.
Lonardi, S.
Engelhardt, M.
Saulay, M.
Schwartz, B.
Shaib, W. L.
Mazzaferro, V.
Papadopoulos, K. P.
ANNALS OF ONCOLOGY, 2019, 30
[2] FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A)
Javle, Milind M.
Shaib, Walid Labib
Braun, Stephan
Engelhardt, Marc
Borad, Mitesh J.
Abou-Alfa, Ghassan K.
Boncompagni, Andrea
Friedmann, Silke
Gahlemann, Christoph Georg
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[3] Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs
Busset, M. Droz Dit
Shaib, W. L.
Harris, W. P.
Damjanov, N.
Borad, M.
Vogel, A.
Bridgewater, J. A.
Sellmann, L.
Dadduzio, V.
Borner, M.
Snider, J.
Cantero, F.
Saulay, M.
Braun, S.
Mazzaferro, V.
Javle, M.
ANNALS OF ONCOLOGY, 2020, 31 : S1231 - S1231
[4] Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01
Javle, Milind M.
Abou-Alfa, Ghassan K.
Macarulla, Teresa
Personeni, Nicola
Adeva, Jorge
Bergamo, Francesca
Malka, David
Vogel, Arndt
Knox, Jennifer J.
Evans, T. R. Jeffry
Dimova-Dobreva, Miryana
Harris, William Proctor
Saulay, Mikael
Engelhardt, Marc
Braun, Stephan
Busset, Michele Droz Dit
Borad, Mitesh J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[5] FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)
Almquist, D. R.
Javle, M.
Ciombor, K. K.
Roth, M.
Abdel-Wahab, R.
Ou, F-S.
Wolfe, E.
Mody, K.
Mahipal, A.
Borad, M. J.
Bekaii-Saab, T.
Ahn, D.
ANNALS OF ONCOLOGY, 2019, 30
[6] Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Hollebecque, A.
Valle, J. W.
Morizane, C.
Karasic, T. B.
Abrams, T. A.
Kelley, R. K.
Cassier, P. A.
Klumpen, H-J.
Uboha, N.
Mahipal, A.
Mitchell, E.
Ahn, E.
Chang, H-M.
Masuda, K.
He, Y.
Benhadji, K. A.
Bridgewater, J. A.
ANNALS OF ONCOLOGY, 2020, 31 : S1288 - S1289
[7] Foenix-CCA2 quality of life data for Futibatinib-treated intrahepatic cholangiocarcinoma (ICCA) patients with FGFR2 fusions/rearrangements
Moehler, M.
Valle, J. W.
Hollebecque, A.
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Epstein, R.
Salimi, T.
Wacheck, V
Liu, M.
Benhadji, K. A.
Bridgewater, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 223 - 224
[8] Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01
Busset, M. Droz Dit
Shaib, W. L.
Mody, K.
Personeni, N.
Damjanov, N.
Harris, W. P.
Bergamo, F.
Brandi, G.
Masi, G.
Halfdanarson, T. R.
Tam, V.
Goff, L. W.
Knox, J.
Hollebecque, A.
Macarulla Mercade, T.
Cantero, F.
Saulay, M.
Braun, S.
Javle, M.
Borad, M.
ANNALS OF ONCOLOGY, 2021, 32 : S376 - S376
[9] Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Morizane, Chigusa
Valle, Juan W.
Karasic, Thomas Benjamin
Abrams, Thomas Adam
Kelley, Robin Kate
Cassier, Philippe Alexandre
Furuse, Junji
Klumpen, Heinz-Josef
Chang, Heung-Moon
Chen, Li-Tzong
Komatsu, Yoshito
Masuda, Kunihiro
Ahn, Daniel H.
Li, Kate
Benhadji, Karim A.
Wacheck, Volker
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma
Cao, Zi
Yang, Yichen
Liu, Shasha
Sun, Lin
Liu, Yanxue
Luo, Ye
Wang, Jian
Sun, Yan
JOURNAL OF GASTROENTEROLOGY, 2025, 60 (02) : 235 - 246

← 1 2 3 4 5 →